On April 25, 2025, Summit Therapeutics Inc. reported that its partner, Akeso, Inc., received approval from Chinese health authorities for ivonescimab for a second indication, following a Phase III clinical trial, with a reported hazard ratio of 0.777 at 39% data maturity.